Rhythm Leans On Imcivree Rare Disease Commercialization For New Indication

 
• By Alaric DeArment
  
Rhythm Pharmaceuticals won FDA approval for Imcivree in Bardet-Biedl syndrome • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip